Think of cancer as a progressive, dynamic, and evolving disease, not as a single target. It responds to treatment not always as expected because to some degree, cancer is generated by the body of the patient, by mutations, and other things that are actually fundamentally a part of the patient. The immune system is there to protect the body and all of its various manifestations and that can also be transferred to the "cancer", which the body does not consistently and always see as "other", and usually doesn't see as "other". And even after treatment begins, the body has many mechanisms, so you may turn one mechanism on to fight the cancer, meanwhile, another mechanism is undercutting that effort, or maybe more than one other mechanism.
In that context, more tools are better than any one tool. Car-T cells (a type of immune therapy that boomed and has had a lot of focus), for instance, are really good at killing very particular cells with particular markers. That includes beneficial cells often. But they can kill 20 pounds of tumor in a few hours. Unfortunately, those cells are highly engineered and don't stay in the body, and frequently they do not therefore educate the body after they are done, as to what to look for to prevent a recurrence of that cancer. So recurrence is a dirty secret of Car-T cell treatments. It does not get talked about a lot because the miracle of just how fast it works and how immediately the treatment acts, is just very exciting.
But you need multiple mechanisms. So for instance, a DC Cell vaccine like DCVax might, in that context, be utilized in the context of a blood cancer, with Car-T cells. I don't know if that will work, and there might need to be special adjustments to such a dendritic cell treatment to address a blood cancer. But Car-T cells have not been super great with solid tumors so far. Maybe they will find a way to adjust them and they might take the place of Chemo or Radiation, but be more targeted and maybe more effective. The problem is that Car-T treatments can also act so strongly that they kill the patient to kill the cancer. Maybe a weaker Car-T treatment with DCVax, or a similar treatment, might work better.
Doctors will have to see what works best by experimentation and clinical trials.
